KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Halozyme Therapeutics (HALO) over the last 13 years, with Q4 2025 value amounting to $273.4 million.

  • Halozyme Therapeutics' Change in Acquisitions & Divestments rose 22553.94% to $273.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $722.2 million, marking a year-over-year increase of 8258.23%. This contributed to the annual value of $722.2 million for FY2025, which is 8258.23% up from last year.
  • According to the latest figures from Q4 2025, Halozyme Therapeutics' Change in Acquisitions & Divestments is $273.4 million, which was up 22553.94% from $209.6 million recorded in Q3 2025.
  • Halozyme Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $590.0 million during Q2 2022, with a 5-year trough of $15.6 million in Q4 2023.
  • Over the past 5 years, Halozyme Therapeutics' median Change in Acquisitions & Divestments value was $76.9 million (recorded in 2021), while the average stood at $122.3 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first soared by 66759.3% in 2022, then plummeted by 9095.4% in 2023.
  • Halozyme Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $69.8 million in 2021, then tumbled by 71.18% to $20.1 million in 2022, then dropped by 22.52% to $15.6 million in 2023, then soared by 438.34% to $84.0 million in 2024, then surged by 225.54% to $273.4 million in 2025.
  • Its last three reported values are $273.4 million in Q4 2025, $209.6 million for Q3 2025, and $189.1 million during Q2 2025.